BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11350879)

  • 21. Ovarian cancer immunotherapy: opportunities, progresses and challenges.
    Liu B; Nash J; Runowicz C; Swede H; Stevens R; Li Z
    J Hematol Oncol; 2010 Feb; 3():7. PubMed ID: 20146807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies for cancer immunotherapy.
    Weiner LM; Dhodapkar MV; Ferrone S
    Lancet; 2009 Mar; 373(9668):1033-40. PubMed ID: 19304016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma.
    Diaz Y; Gonzalez A; Lopez A; Perez R; Vazquez AM; Montero E
    Cancer Immunol Immunother; 2009 Jul; 58(7):1117-28. PubMed ID: 19066887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen.
    Li W; Cui H; Meng FQ; Chang XH; Zhang G; Liu B; Li ZH
    Cancer Immunol Immunother; 2008 Feb; 57(2):143-54. PubMed ID: 17618437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic applications of monoclonal antibodies.
    Berger M; Shankar V; Vafai A
    Am J Med Sci; 2002 Jul; 324(1):14-30. PubMed ID: 12120821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.
    Foon KA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 2001 May; 7(5):1112-5. PubMed ID: 11350872
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
    Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
    Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
    Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
    Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
    Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.